Tuesday 13 October 2026
Export ENTX’s income statement to Excel — free account
Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.51
0.14
−5.28%
Follow ENTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (138.92%) | (82.33%) | (108.01%) | (99.43%) |
+8 more TTM periods Free account |
|
| (87.02%) | (71.28%) | (90.13%) | (85.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(100.71%) | (112.07%) | (86.47%) | (69.33%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.22) | (0.19) | (0.16) | (0.15) | |
Free Cash Flow |
(10.99) | (9.06) | (7.48) | (7.09) | |
Capital Expenditures |
(0.10) | — | (0.11) | (0.08) | |
| Other line items | |||||
Cash ROIC |
(42.77%) | (40.05%) | (26.72%) | (22.26%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.64 | 0.73 | 0.64 | 0.65 | |
Depreciation/Fixed assets |
0.26 | 0.23 | 0.22 | 0.30 | |
Capex/Depreciation |
(3.29) | 0.00 | (3.57) | (2.44) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.19) | (0.16) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates